Shi Chanjuan, Klimstra David S
Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee.
Department of Pathology, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, New York 10065.
Semin Diagn Pathol. 2014 Nov;31(6):498-511. doi: 10.1053/j.semdp.2014.08.008. Epub 2014 Sep 30.
Pancreatic neuroendocrine neoplasms include mainly well-differentiated neuroendocrine tumors but also rare poorly differentiated neuroendocrine carcinomas. Molecular mechanisms underlying pancreatic neuroendocrine tumorigenesis have recently been elucidated. While alterations in the chromatin remodeling and PI3K/Akt/mTOR pathways are present in most well-differentiated pancreatic neuroendocrine tumors, mutations in TP53 and RB may contribute to the development of pancreatic poorly differentiated neuroendocrine carcinomas. With these discoveries, new molecular targeted therapies have become available and show promise in some patients with pancreatic well-differentiated neuroendocrine tumor.
胰腺神经内分泌肿瘤主要包括高分化神经内分泌肿瘤,但也有罕见的低分化神经内分泌癌。胰腺神经内分泌肿瘤发生的分子机制最近已得到阐明。虽然大多数高分化胰腺神经内分泌肿瘤存在染色质重塑和PI3K/Akt/mTOR通路的改变,但TP53和RB的突变可能有助于胰腺低分化神经内分泌癌的发生。随着这些发现,新的分子靶向治疗已经出现,并在一些胰腺高分化神经内分泌肿瘤患者中显示出前景。